Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in active rheumatoid arthritis refractory to biologic disease-modifying antirheumatic drugs

2020 ◽  
Author(s):  
Y. H. Lee ◽  
G. G. Song
Keyword(s):  
Rheumatoid Arthritis ◽  
Active Rheumatoid Arthritis ◽  
Efficacy And Safety ◽  
Comparative Efficacy ◽  
Disease Modifying Antirheumatic Drugs ◽  
Antirheumatic Drugs ◽  
Disease Modifying

scholarly journals EFFICACY AND SAFETY OF GOLIMUMAB AS ADD-ON THERAPY TO DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN RHEUMATOID ARTHRITIS: RESULTS OF THE GO-MORE STUDY IN ROMANIA

2015 ◽  
Vol 24 (4) ◽  
pp. 207-213
Author(s):  
Simona Rednic ◽  
◽  
Magda Parvu ◽  
Catalin Codreanu ◽  
Ioan Ancuta ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Safety Profile ◽  
Active Rheumatoid Arthritis ◽  
Safety Data ◽  
Efficacy And Safety ◽  
Disease Modifying Antirheumatic Drugs ◽  
Antirheumatic Drugs ◽  
Open Label ◽  
Disease Characteristics ◽  
Disease Modifying

Objectives. GO-MORE was an open-label, multinational, prospective observational study in patients with active rheumatoid arthritis (RA) in typical clinical practice settings in 40 countries. The trial involved patients with active rheumatoid arthritis despite treatment with disease modifying antirheumatic drugs (DMARDs) and naïve to biological agents. Considering the different countries demographic or disease characteristics, we analysed the efficacy and safety data of the Romanian subpopulation in this paper. Method. The patients received subcutaneous GOL 50 mg once a month for a period of 6 months. The primary endpoint was the percentage of patients with a good and moderate EULAR DAS28-ESR response after 6 months of treatment. Results. A total of 51 patients with active RA with an average disease duration of 3.53 years and an average DAS28 of 6.15 at baseline were included. All patients were taking DMARDs (66% patients were taking methotrexate (MTX) and 23.5% leflunomide (LEF) in monotherapy; the others were taking other background therapies or combinations of them). All these 51 patients received GOL 50 mg once a month. After 6 months 78.4% of patients showed a good or moderate EULAR response, most of them (68.6%) after the first administration; 27.5% showed low DAS28-ESR and 7.8% were in remission. GOL was well tolerated and the safety profile was consistent with the findings of previous studies. The number of serious side effects (12%) or which lead to discontinuation of therapy (8%) was generally low. Conclusions. The addition of subcutaneous GOL 50 mg once a month to different DMARDs in patients with active RA yielded a moderate or good EULAR DAS28-ESR response after 6 month in a proportion of 78.4% of patients in Romania. The response was observed after the first administration of GOL. The safety profile is consistent with other clinical trials with antiTNFi in RA with no new safety signals detected.

scholarly journals Comparative efficacy and safety of Janus kinase inhibitors and biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and network meta-analysis

2021 ◽  
Vol 13 ◽  
pp. 1759720X2199956
Author(s):  
Chenghua Weng ◽  
Leixi Xue ◽  
Qing Wang ◽  
Wentian Lu ◽  
Jiajun Xu ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Meta Analysis ◽  
Certolizumab Pegol ◽  
Janus Kinase ◽  
Efficacy And Safety ◽  
Jak Inhibitors ◽  
Comparative Efficacy ◽  
Disease Modifying Antirheumatic Drugs ◽  
Antirheumatic Drugs ◽  
Disease Modifying

Objective: To evaluate the comparative efficacy and safety of Janus kinase (JAK) inhibitors and biological disease-modifying antirheumatic drugs (bDMARDs) in patients with rheumatoid arthritis (RA) and an inadequate response to at least one disease-modifying antirheumatic drug (DMARD). Methods: PubMed, Embase, Cochrane library and ClinicalTrials.gov were searched for relevant randomized controlled trials (RCTs) from inception to April 2020. The active drugs included three JAK inhibitors and eight bDMARDs while the control drugs included placebo or conventional synthetic disease-modifying antirheumatic drugs (csDMARDs). Outcomes include American College of Rheumatology 20% response (ACR20), Disease Activity Score in 28 joints (DAS28), Health Assessment Questionnaire–Disability Index (HAQ-DI) and discontinuations for adverse events (AEs). We estimated summary odds ratios (ORs) and weighted mean differences (WMDs) using network meta-analysis with random effects. Results: Eighty-eight RCTs with 31,566 patients were included. All JAK inhibitors and bDMARDs were more effective than placebo in ACR20 (ORs ranging between 3.05 and 5.61), DAS28 (WMDs ranging between −1.91 and −0.80) and HAQ-DI (WMDs ranging between −0.34 and −0.21). Tocilizumab, certolizumab pegol and upadacitinib showed relatively good efficacy in these three outcomes according to their relative ranking. Notably, tocilizumab was more effective than other active drugs in DAS28 (WMDs ranging between −1.11 and −0.49). Compared with the lower recommended doses, increasing the doses of JAK inhibitors (baricitinib 4 mg versus 2 mg, tofacitinib 10 mg versus 5 mg and upadacitinib 30 mg versus 15 mg) cannot provide significant additional benefits. In terms of discontinuations for AEs, all active drugs showed no significant difference compared with placebo except certolizumab pegol [OR 1.65, 95% credible interval (CrI) 1.06–2.61] and rituximab (3.17, 1.11–10.80). Conclusions: Tocilizumab, certolizumab pegol and upadacitinib may have relatively good efficacy in patients with RA after treatment failure with csDMARDs. RA patients taking a JAK inhibitor may have a preference for a lower recommended dose.

Efficacy and Safety of Hepatitis B Vaccination in Rheumatoid Arthritis Patients Receiving Disease-Modifying Antirheumatic Drugs and/or Biologics Therapy

2018 ◽  
pp. 1 ◽  
Author(s):  
Samanan Intongkam ◽  
Parinya Samakarnthai ◽  
Rattapol Pakchotanon ◽  
Pongthorn Narongroeknawin ◽  
Paijit Assavatanabodee ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Hepatitis B ◽  
Hepatitis B Vaccination ◽  
Efficacy And Safety ◽  
Disease Modifying Antirheumatic Drugs ◽  
Antirheumatic Drugs ◽  
Disease Modifying

scholarly journals Sarilumab monotherapy or in combination with non-methotrexate disease-modifying antirheumatic drugs in active rheumatoid arthritis: A Japan phase 3 trial (HARUKA)

2019 ◽  
Vol 30 (2) ◽  
pp. 239-248 ◽  
Author(s):  
Hideto Kameda ◽  
Kazuteru Wada ◽  
Yoshinori Takahashi ◽  
Owen Hagino ◽  
Hubert van Hoogstraten ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Active Rheumatoid Arthritis ◽  
Disease Modifying Antirheumatic Drugs ◽  
Antirheumatic Drugs ◽  
Phase 3 ◽  
Disease Modifying

Efficacy and Safety of Golimumab as Add-on Therapy to Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis: Results of the GO-MORE Study in Spain

2015 ◽  
Vol 11 (3) ◽  
pp. 144-150
Author(s):  
Alberto Alonso ◽  
Carlos M. González ◽  
Javier Ballina ◽  
María L. García Vivar ◽  
Juan J. Gómez-Reino ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Efficacy And Safety ◽  
Disease Modifying Antirheumatic Drugs ◽  
Antirheumatic Drugs ◽  
Disease Modifying

scholarly journals Active rheumatoid arthritis with multiple pulmonary nodules failure to multiple remissive therapy: Which is the solution?

2021 ◽  
Vol 30 (3) ◽  
pp. 125-128
Author(s):  
Ileana Cosmina Filipescu ◽  
◽  
Milena Man ◽  
Simona Rednic ◽  
◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Active Rheumatoid Arthritis ◽  
Pulmonary Nodules ◽  
Lung Nodules ◽  
Imaging Studies ◽  
Disease Modifying Antirheumatic Drugs ◽  
Antirheumatic Drugs ◽  
History Of ◽  
Disease Modifying ◽  
Anti Fungal

We describe the case of a 63-year-old nonsmoker woman, with a long history of active seropositive rheumatoid arthritis, failure to multiple disease-modifying antirheumatic drugs due to both loss of efficacy and adverse drug reaction. She was exposed to silicon dust some years ago and has many pulmonary nodules, revealed by imaging studies as multiple cavitary lung nodules. Her initial pathological samples were negative for any infections and treatment against tuberculosis and anti-fungal therapy did not improve the appearance of the nodules. After an extensive reevaluation of pulmonary nodules, the Baricitinib treatment was started.

Sign in / Sign up

Export Citation Format

Share Document